Sentences with phrase «reduced abilities for»

As a result, reduced abilities for cell growth, migration and invasion were found.

An Agion treatment reduces the ability for mold and mildew to grow in your bag.

The EU is setting up for later negotiations, to reduce the ability for the UK to apply for that special treatment when they rejoin.

In the past couple of years, the use of foam rollers has skyrocketed in the wellness world for its tension - relieving and stress - reducing abilities for both the mind and body.

Additionally, reducing the ability for outdoor creatures (raccoons, skunk, rabbit, etc.) to enter your yard, closing windows and doors, repairing construction defects that could harbor fleas, and preventing your pets from going to areas potentially infested with fleas (boarding facilities, dog parks, etc.) are other ways humans can prevent a parasitic invasion.

By divesting their assets from fossil fuels, they are reducing the ability for big oil, coal and gas companies to develop new extraction projects, while citizens worldwide are rising to stop these projects in their communities,» said Yossi Cadan, Global Divestment Senior Campaigner at 350.org.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

One research project, for example, focuses on using robots to recognize the facial reactions of Parkinson's Disease patients who have lost the ability to convey emotion to others because of reduced muscle activity.

«The ability to obtain accurate measurements and clear images from aerial photographs will significantly reduce the amount of time highways are closed during the initial investigation of major traffic crashes,» a state police statement gave as reasons for seeking to use what - shall - not - be-called-drones.

The clean energy industry's continued ability to cut costs and reduce the demand for fossil fuels is pivotal to its success in the coming years.

Actual results, including with respect to our targets and prospects, could differ materially due to a number of factors, including the risk that we may not obtain sufficient orders to achieve our targeted revenues; price competition in key markets; the risk that we or our channel partners are not able to develop and expand customer bases and accurately anticipate demand from end customers, which can result in increased inventory and reduced orders as we experience wide fluctuations in supply and demand; the risk that our commercial Lighting Products results will continue to suffer if new issues arise regarding issues related to product quality for this business; the risk that we may experience production difficulties that preclude us from shipping sufficient quantities to meet customer orders or that result in higher production costs and lower margins; our ability to lower costs; the risk that our results will suffer if we are unable to balance fluctuations in customer demand and capacity, including bringing on additional capacity on a timely basis to meet customer demand; the risk that longer manufacturing lead times may cause customers to fulfill their orders with a competitor's products instead; the risk that the economic and political uncertainty caused by the proposed tariffs by the United States on Chinese goods, and any corresponding Chinese tariffs in response, may negatively impact demand for our products; product mix; risks associated with the ramp - up of production of our new products, and our entry into new business channels different from those in which we have historically operated; the risk that customers do not maintain their favorable perception of our brand and products, resulting in lower demand for our products; the risk that our products fail to perform or fail to meet customer requirements or expectations, resulting in significant additional costs, including costs associated with warranty returns or the potential recall of our products; ongoing uncertainty in global economic conditions, infrastructure development or customer demand that could negatively affect product demand, collectability of receivables and other related matters as consumers and businesses may defer purchases or payments, or default on payments; risks resulting from the concentration of our business among few customers, including the risk that customers may reduce or cancel orders or fail to honor purchase commitments; the risk that we are not able to enter into acceptable contractual arrangements with the significant customers of the acquired Infineon RF Power business or otherwise not fully realize anticipated benefits of the transaction; the risk that retail customers may alter promotional pricing, increase promotion of a competitor's products over our products or reduce their inventory levels, all of which could negatively affect product demand; the risk that our investments may experience periods of significant stock price volatility causing us to recognize fair value losses on our investment; the risk posed by managing an increasingly complex supply chain that has the ability to supply a sufficient quantity of raw materials, subsystems and finished products with the required specifications and quality; the risk we may be required to record a significant charge to earnings if our goodwill or amortizable assets become impaired; risks relating to confidential information theft or misuse, including through cyber-attacks or cyber intrusion; our ability to complete development and commercialization of products under development, such as our pipeline of Wolfspeed products, improved LED chips, LED components, and LED lighting products risks related to our multi-year warranty periods for LED lighting products; risks associated with acquisitions, divestitures, joint ventures or investments generally; the rapid development of new technology and competing products that may impair demand or render our products obsolete; the potential lack of customer acceptance for our products; risks associated with ongoing litigation; and other factors discussed in our filings with the Securities and Exchange Commission (SEC), including our report on Form 10 - K for the fiscal year ended June 25, 2017, and subsequent reports filed with the SEC.

For $ 6.99 a month or $ 69.99 a year, you get access to clips over seven - day periods, person detection, and the ability to set up zones to reduce unnecessary alerts.

Beyond that the adrenal gland responsible for secreting the stress response hormone becomes fatigued, resulting in decreased immunity to infection, reduced ability to repair the body and increased inflammation and tissue damage.

There are still some functions available from the old platform, however, such as the ability to read public media on behalf of a user or to read a user's own media statistics, although the number of requests (the number of times your app accesses Instagram's data, useful for real - time updates) has been reduced to 200 from 5,000.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

For example, the expected timing and likelihood of completion of the proposed merger, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed merger that could reduce anticipated benefits or cause the parties to abandon the transaction, the ability to successfully integrate the businesses, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, the possibility that Kraft shareholders may not approve the merger agreement, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Kraft's common stock, and the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Kraft and Heinz to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally, problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected, the combined company may be unable to achieve cost - cutting synergies or it may take longer than expected to achieve those synergies, and other factors.

Our funds may be affected by reduced opportunities to exit and realize value from their investments, by lower than expected returns on investments made prior to the deterioration of the credit markets and by the fact that we may not be able to find suitable investments for the funds to effectively deploy capital, all of which could adversely affect the timing of new funds and our ability to raise new

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Other risks and uncertainties include the timing and likelihood of completion of the proposed transactions between ILG and MVW, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals for the proposed transactions that could reduce anticipated benefits or cause the parties to abandon the transactions; the possibility that ILG's stockholders may not approve the proposed transactions; the possibility that MVW's stockholders may not approve the proposed transactions; the possibility that the expected synergies and value creation from the proposed transactions will not be realized or will not be realized within the expected time period; the risk that the businesses of ILG and MVW will not be integrated successfully; disruption from the proposed transactions making it more difficult to maintain business and operational relationships; the risk that unexpected costs will be incurred; the ability to retain key personnel; the availability of financing; the possibility that the proposed transactions do not close, including due to the failure to satisfy the closing conditions; as well as more specific risks and uncertainties.

There were two design features of the SCAP program that were essential for its ability to reduce the uncertainty in financial markets.

During the boom of the 1990s, neoliberal economists and the financial press promoted the the high tech revolution for its ability to reduce production costs.

An Interview with Michael Hudson for Counterpunch By STANDARD SCHAEFER During the boom of the 1990s, neoliberal economists and the financial press promoted the the high tech revolution for its ability to reduce production costs.

While this reduces the reported amount of outstanding debt, if the concern is the ability of borrowers to generate the returns needed to service the debt that funded these projects, converting them into equity does not reduce the riskiness of the banking system, nor does it reduce net indebtedness for the country overall.

Broker - dealers have little appetite for inventory, thereby reducing the ability of markets to facilitate normal risk transfer.

FIC Network is a blockchain - based fixed income securities model that reduces costs, operational friction, and risks while improving auditing ability and transparency for the industry.

Such fees create unnecessary hurdles for adopting DApps with internal tokens, reducing their ability to build out a large user base even as they attract significant mainstream attention.

One of the areas that has taken away from ability to save for new purchases is my goal to have a cash balance of 10 % in my 401K to reduce risk.

The ability to reduce overall healthcare costs by leveraging innovative, compliant, and holistic PBM solutions is one of the biggest opportunities that exist for plan sponsors.

The new free experience will also have the ability to cache songs — which reduces the amount of data needed for streaming — based on listening habits.

«These findings, although currently laboratory - based, could have deep implications for the detection and treatment of corneal infections as it has the potential to reduce diagnosis time from up to two weeks to only a few minutes - and the ability to deliver the correct antibiotics immediately.»

The inventory for privatization now includes the accumulated knowledge and memory of the people, the cultural and religious wisdom as well as symbols and people's ability to find pleasure are reduced as a commodity in the market place.

It would reduce the ability of mainstream news and entertainment media to provide cover for liberal politicians.

For even the apparent success of the reductionist hypothesis in certain areas does not by any means imply the practicability of a «constructionist» one — to reduce everything to simple fundamental laws does not imply the ability to start from those laws and reconstruct the universe.

Reducing alcohol consumption and fatigue, and shifting to nondemanding pleasuring for a while (to reduce the anxiety about failure and the pressure to succeed) usually restores fully the ability to function.

They run the organization with a what's good for the organitazion in mind and often the people who want to ask questions, who struggle to meet performance expectations -LCB- the christian walk is reduced to performance giving, serving - the church organization, keeping sins off a particular list (ignoring the heart) and an ability to regurgitate spoon fed theology -RCB- the low performers are «disciplined» into performing outwardly regardless of inward conditions or are left in the dust of the organizations progress.

Loosing weight is a very important for diabetics, because fat cells reduce your body's ability to move sugar into cells and use it as energy.

It is well - known for its ability to assist in increasing levels of dopamine and serotonin — neurotransmitters that control the brain's reward and pleasure centers, reduce stress and stabilize mood.

The ability of corrugated packaging to increase shelf - life could translate into significantly reduced shrink and potentially millions of dollars in savings for retailers.»

Caffeine is touted for its ability to help reduce redness and under eye circles, support circulation and even help manage cellulite.

The Journal of Alternative and Complementary Medicine, goji berry benefits include increased ratings for energy levels, athletic performance, quality of sleep, ease of awakening, ability to focus on activities, mental acuity, calmness, feelings of health, contentment, and happiness and significantly reduced fatigue and stress.

Sesame Seeds Sesame seeds are extremely beneficial for health as they include the ability to prevent diabetes, lower blood pressure, build strong bones, increase heart health, help with sleep disorders, improve digestion, reduce inflammation, boost respiratory health, strengthen oral health, improve circulation and detoxify the body.

(For more nutritional information about cauliflower, including its cancer - reducing ability, visit The World's Healthiest Foods.)

Soybeans are full of isoflavones, the phytochemical that may be responsible for soybeans» ability to lower cholesterol and reduce cancer risk.

Chosen for its reduced footprint and ability to meet the stringent quality standards of the UK's major retailers, this latest machine is inspecting different size packs of speciality Stilton cheeses.

Chosen for its reduced footprint and ability to meet the -LSB-...]

With the ability to decorate the complete package, this breakthrough technology eliminates the need for label substrates reduces landfill scrap, as well as reducing the time to market for new designs.

However, despite this ability, his contribution to build - up is arguably reduced by the team he plays for.

I do nt beleive a player enjoys playing at a reduced ability and also play cra * for too long and they risj their own market values.

Everyone has a quota (12 of 25) must be home grown, he has had his injury problems but getting rid of him solves nothing... For one it just reduces our ability to match that quota, secondly English talent is overpriced so getting a replacement wont be easy or cheap so its a ridiculous thing to even suggest.

I say that because Sanchez will have a difficult choice to make: If no one improves our offer (assuming there is one) before the window closes and he chooses to play his contract out he runs the risk of having a serious injury midway through the season which will reduce his ability to get the kind of five year contract I am sure he is hoping for, where as if he accepts ours he is safe for the next, extremely important and perhaps the last five years of his playing career but one thing is sure and I say it again only a fool would sign before exploring all the possibilities and that in itself made and makes it impossible for the club to have «made» him sign earlier.